Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical
stage biotechnology company developing innovative therapeutics for
fibro-inflammatory diseases with high unmet need, today reported
that it presented two scientific posters supporting the clinical
rationale for the company’s primary sclerosing cholangitis (PSC)
program at EASL 2024, the Annual Congress of the European
Association for the Study of the Liver, which is taking place June
5-8, 2024 in Milan, Italy. Chemomab also announced a poster
presentation at the Gordon Research Conference on Chemotactic
Cytokines, held June 2-7, 2024 in Portland, Maine.
The presentations cover a range of topics, from new preclinical
studies further elucidating the roles of the novel soluble protein
target CCL24 and Chemomab’s CCL24-neutralizing antibody CM-101 in
fibro-inflammatory liver disorders, to translational research
supporting the clinical development of CM-101 for PSC, a rare and
often fatal liver disease.
The first EASL poster describes an ex vivo-developed
translational assay designed to further characterize the
anti-fibrotic activity of CM-101 in patients with liver disease.1
This study was selected for an EASL 2024 Poster Tour highlighting
presentations of special interest. Using a serum-based ex vivo
hepatic stellae cell (HSC) activation assay derived from patients
with liver fibrosis due to metabolic dysfunction-associated
steatohepatitis (MASH), the study showed that sera from these
patients directly activates HSCs and that HSC activation levels
were significantly reduced in the sera of patients treated with
CM-101. Importantly, a protein signature generated from
CCL24-activated HSCs was able to predict PSC disease and its
severity. These findings support CM-101’s mode of action in liver
fibrosis and are expected to help in characterizing its
anti-fibrotic drug effects by serving as a translational tool in
PSC clinical trials.
In a second poster2, researchers presented a comprehensive
proteomic profiling study of patients with PSC, which was combined
with machine learning-based methods to develop a protein signature
model that successfully predicted the presence and severity of
PSC when combined with proteins correlated with the Enhanced Liver
Function (ELF) biomarker score. The machine learning analysis was
also able to identify key proteins associated with PSC progression.
Additionally, the model showed that high CCL24 levels were
associated with cirrhosis in patients with PSC. The findings
emphasize the value of targeting CCL24 in PSC treatment.
“As we approach the topline readout of our CM-101 Phase 2 PSC
trial, we welcome the opportunity to highlight important new data
at EASL 2024 and at a prestigious Gordon Research Conference,”
noted Adi Mor, PhD, co-founder, Chief Executive Officer and Chief
Scientific Officer of Chemomab. “We are especially excited about
the novel translational work from our R&D team included in two
presentations at EASL. In one, an ex vivo translational assay we
developed confirmed that serum from patients with liver fibrosis
activates HSCs, a key driver of PSC pathology, and that
administration of CM-101 significantly reduces this HSC activation,
indicating that inhibition of CCL24 is sufficient to attenuate HSC
activation. The second study presented a proteomics and machine
learning-based PSC protein signature model developed by Chemomab
researchers that has potential as a biomarker for monitoring and
assessing drug activity in current and future clinical trials of
CM-101.”
The Gordon Conference presentation3 highlighted preclinical
studies that provide further evidence of the key role of CCL24 in
driving fibro-inflammatory pathways in liver diseases such as
primary sclerosing cholangitis, as well as the ability of
Chemomab’s CCL24-neutralizing antibody CM-101 to block these
effects and attenuate inflammation and fibrosis.
The posters will be available post-conference on the Chemomab
website at www.chemomab.com/r-d/.
1 - Ex-vivo translational assay of hepatic stellate cells using
patient-derived serum characterizes the anti-fibrotic activity of
CM-101, J Amer, A Salhab, R Greenman, A Katav, T Snir, R Aricha, M
Frankel, J Lawler, F Saffioti, D Thorburn, M Pinzani, I Vaknin, A
Mor and R Safadi, June 6, 2024, Fibrosis/Stellate cell biology
session, EASL abstract #380
2 - Machine learning-driven identification of serum protein
signature for primary sclerosing cholangitis and enhanced liver
fibrosis score, T Snir, R Greenman, A Katav, R Aricha, M Frankel, J
Lawler, F Saffioti, D Thorburn, M Pinzani, I Vaknin, A Mor, June 6,
2024, Immune-mediated and cholestatic: Experimental and
pathophysiology session, EASL abstract #1032
3 - Attenuating liver fibrosis and inflammation: blocking CCL24
inhibits recruitment of hepatic stellate cells, monocytes and
neutrophils and modulates hepatic stellate cell activation, R
Greenman, O Hay, I Mishalian, I Vaknin, M Pinzani, D Thorburn, J
Amer, A Salhab, R Safadi, A Mor, A Peled, June 2-7, 2024, Gordon
Research Conference on Chemotactic Cytokines
Forward Looking Statements This press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act. These forward-looking
statements include, among other things, the clinical development
pathway for CM-101; the expectation that Chemomab will report
topline data from the PSC clinical trial by mid-year 2024; the
length, duration and impact of the war in Israel on Chemomab’s
business and operations; the future operations of Chemomab and its
ability to successfully initiate and complete clinical trials and
achieve regulatory milestones; the nature, strategy and focus of
Chemomab; the development and commercial potential and potential
benefits of any product candidates of Chemomab; and that the
product candidates have the potential to address high unmet needs
of patients with serious fibrosis-related diseases and conditions.
Any statements contained in this communication that are not
statements of historical fact may be deemed to be forward-looking
statements. These forward-looking statements are based upon
Chemomab's current expectations. Forward-looking statements involve
risks and uncertainties. Because such statements deal with future
events and are based on Chemomab's current expectations, they are
subject to various risks and uncertainties and actual results,
performance or achievements of Chemomab could differ materially
from those described in or implied by the statements in this
presentation, including those found under the caption "Risk
Factors" and elsewhere in Chemomab's filings and reports with the
SEC. Chemomab expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Chemomab's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based,
except as required by law.
About Chemomab Therapeutics Ltd.Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of CCL24 in promoting fibrosis
and inflammation, Chemomab developed CM-101, a monoclonal antibody
that neutralizes CCL24 activity. In clinical and preclinical
studies, CM-101 appears safe, with the potential to treat multiple
severe and life-threatening fibro-inflammatory diseases. Chemomab
has reported positive results from three clinical trials of CM-101
in patients, including a Phase 2a liver fibrosis trial in NASH
patients and an investigator-initiated study in patients with
severe lung injury. A Phase 2 trial in primary sclerosing
cholangitis has completed patient enrollment, with topline data
expected midyear 2024. Chemomab’s CM-101 program for the treatment
of systemic sclerosis is Phase 2-ready with an open U.S. IND. For
more information about Chemomab, visit chemomab.com.
Contacts:
Media & Investors:Chemomab
TherapeuticsBarbara LindheimConsulting Vice PresidentInvestor &
Public Relations, Strategic CommunicationsPhone: +1
917-355-9234barbara.lindheim@chemomab.com IR@chemomab.com
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Chemomab Therapeutics (NASDAQ:CMMB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024